Table 2 Characteristics of patients with different types of BM
Characteristics | Osimertinib after BM | Osimertinib before BM | P | Total |
|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | ||
Age | ||||
 < 60 | 12 (22.2%) | 8 (14.8%) | 0.898 | 20 (37.0%) |
 ≥ 60 | 21 (38.9%) | 13 (24.1%) |  | 34 (63.0%) |
Gender | ||||
 Male | 18 (33.3%) | 8 (14.8%) | 0.238 | 26 (48.1%) |
 Female | 15 (27.8%) | 13 (24.1%) |  | 28 (51.9%) |
Smoking history | ||||
 Yes | 13(24.1%) | 5 (9.3%) | 0.236 | 18 (33.3%) |
 No | 20 (37.0%) | 16 (29.6%) |  | 36 (66.7%) |
EGFR mutation | ||||
 19 del | 16 (29.6%) | 14 (25.9%) | 0.190 | 30 (55.6%) |
 21 L858R | 17 (31.5%) | 7 (13.0%) |  | 24 (44.4%) |
ECOG-PS | ||||
 0–1 | 29 (53.7%) | 19 (35.2%) | 0.767 | 48 (88.9%) |
 2–3 | 4 (7.4%) | 2 (3.7%) |  | 6 (11.1%) |
Size of the largest BM (cm) | ||||
 < 1 | 25 (46.3) | 13 (24.1) | 0.277 | 38 (70.4%) |
 ≥ 1 | 8 (14.8) | 8 (14.8) |  | 16 (29.6%) |
Number of BM | ||||
 ≤ 3 | 9 (16.7%) | 5 (9.3%) | 0.777 | 14 (26.0%) |
 > 3 | 24 (44.4%) | 16 (29.6%) |  | 40 (74.0%) |
Symptom of BM | ||||
 Yes | 7 (13.0%) | 5 (9.3%) | 0.823 | 12 (22.2%) |
 No | 26 (48.2%) | 16 (29.6%) |  | 42 (77.8%) |
DS-GPA | ||||
 0–1.5 | 8 (14.8%) | 7 (13.0%) | 0.467 | 15 (27.8%) |
 2–4 | 25 (46.3%) | 14 (25.9%) |  | 39 (72.2%) |
Radiotherapy (BM) | ||||
 WBRT/SRS | 22 (40.7%) | 15 (27.8%) | 0.713 | 37 (68.5%) |
 No | 11 (20.4%) | 6 (11.1%) |  | 17 (31.5%) |